<DOC>
	<DOC>NCT00872534</DOC>
	<brief_summary>To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective doses of aspirin (325 mg) in normal healthy volunteers.</brief_summary>
	<brief_title>Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<criteria>Subject is ≥50 to ≤75 years of age. Subject is healthy. Subject has a BMI between 20 and 32 If female and of child bearing potential, subject has a negative pregnancy test and is not nursing. Subject has abnormal screening/baseline laboratory parameters or endoscopic observations deemed clinically significant by the Investigator. Subject has an active Helicobacter pylori infection. Subject has a prior GI ulcer, bleeding, obstruction or perforation. Subject has taken aspirin or any aspirin containing product within the last 4 weeks, or a nonaspirin NSAID product within 2 weeks. Subject has taken any of the following medications within 2 weeks prior to enrollment: Any antiplatelet agents, anticoagulants or selective serotonin reuptake inhibitors. Subject has used an investigational agent within the past 30 days. Subject has hypersensitivity or contraindications to aspirin, ibuprofen, or other NSAID.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>To evaluate the acute gastrointestinal safety of PL-2100.</keyword>
</DOC>